Status:
UNKNOWN
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage
Lead Sponsor:
University of Sao Paulo
Conditions:
Recurrent
Hemorrhage
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. There have been efforts to lower the incidence of postoperative vitreous hemorrhage ...
Eligibility Criteria
Inclusion
- patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy
Exclusion
- follow-up period of less than 3 months
- not first vitrectomy
- abnormal blood coagulation
- uncontrolled hypertension
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01151722
Start Date
December 1 2009
Last Update
June 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clínicas de Ribeirão Preto - University of São Paulo
Ribeirão Preto, São Paulo, Brazil, 14049-990